BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Holmes EC, Hurt AC, Dobbie Z, Clinch B, Oxford JS, Piedra PA. Understanding the Impact of Resistance to Influenza Antivirals. Clin Microbiol Rev 2021;34:e00224-20. [PMID: 33568554 DOI: 10.1128/CMR.00224-20] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Jones WA, Castro RC, Masters HL 3rd, Carrico R. Influenza Management During the COVID-19 Pandemic: A Review of Recent Innovations in Antiviral Therapy and Relevance to Primary Care Practice. Mayo Clin Proc Innov Qual Outcomes 2021;5:974-91. [PMID: 34414356 DOI: 10.1016/j.mayocpiqo.2021.07.005] [Reference Citation Analysis]
2 Chen W, Shao J, Ying Z, Du Y, Yu Y. Approaches for discovery of small-molecular antivirals targeting to influenza A virus PB2 subunit. Drug Discov Today 2022:S1359-6446(22)00085-X. [PMID: 35247593 DOI: 10.1016/j.drudis.2022.02.024] [Reference Citation Analysis]
3 Hurt AC, Wheatley AK. Neutralizing Antibody Therapeutics for COVID-19. Viruses 2021;13:628. [PMID: 33916927 DOI: 10.3390/v13040628] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
4 Bdeir N, Arora P, Gärtner S, Pöhlmann S, Winkler M. Evidence that two instead of one defective interfering RNA in influenza A virus-derived defective interfering particles (DIPs) does not enhance antiviral activity. Sci Rep 2021;11:20477. [PMID: 34650149 DOI: 10.1038/s41598-021-99691-1] [Reference Citation Analysis]
5 Pascua PNQ, Jones JC, Marathe BM, Seiler P, Caufield WV, Freeman BB 3rd, Webby RJ, Govorkova EA. Baloxavir Treatment Delays Influenza B Virus Transmission in Ferrets and Results in Limited Generation of Drug-Resistant Variants. Antimicrob Agents Chemother 2021;65:e0113721. [PMID: 34424039 DOI: 10.1128/AAC.01137-21] [Reference Citation Analysis]